Recombinant Human Complement Factor H/CFH protein (His Tag)

Catalog Number: PDMH100401

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description		
Species	Human	
Source	HEK293 Cells-derived Human Complement Factor H protein Ser860-Arg1231, with an	
	C-terminal His	
Calculated MW	40.8 kDa	
Observed MW	60 kDa	
Accession	P08603	
Bio-activity	Not validated for activity	
Properties		
Purity	> 95% as determined by reducing SDS-PAGE.	
Endotoxin	< 1.0 EU/mg of the protein as determined by the LAL method	
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80	
	°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of	
C1 • •	reconstituted samples are stable at < -20 C for 5 months.	
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.	
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with 5% Trehalose and 5%	
	Mannitol.	
Reconstitution	It is recommended that sterile water be added to the vial to prepare a stock solution of	
	0.5 mg/mL. Concentration is measured by UV-Vis.	

Data

KDa	MK	R
116		
66.2	-	-
45.0	-	
35.0	-	
25.0	-	
18.4	-	
14.4	-	

> 95 % as determined by reducing SDS-PAGE.

Background

Elabscience®

Complement factor H, also known as H factor 1, and CFH, is a sialic acid containing glycoprotein that plays an integral role in the regulation of the complement-mediated immune system that is involved in microbial defense, immune complex processing, and programmed cell death. Factor H protects host cells from injury resulting from unrestrained complement activation. CFH regulates complement activation on self cells by possessing both cofactor activity for the Factor I mediated C3b cleavage, and decay accelerating activity against the alternative pathway C3 convertase, C3bBb. CFH protects self cells from complement activation but not bacteria/viruses. Due to the central role that CFH plays in the regulation of complement, there are many clinical implications arrising from aberrant CFH activity. Mutations in the Factor H gene are associated with severe and diverse diseases including the rare renal disorders hemolytic uremic syndrome (HUS) and membranoproliferative glomerulonephritis (MPGN) also termed dense deposit disease (DDD), membranoproliferative glomuleronephritis type II or dense deposit disease, as well as the more frequent retinal disease age related macular degeneration (AMD). In addition to its complement regulatory activities, factor H has multiple physiological activities and 1) acts as an extracellular matrix component, 2) binds to cellular receptors of the integrin typ e, and 3) interacts with a wide selection of ligands, such as the C-reactive protein, thrombospondin, bone sialoprotein, osteopontin, and heparin.